Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ABBVIE LIMITED,Upadacitinib,Treatment of moderate to severe atopic dermatitis,Upadacitinib (RINVOQÂ®),,Community,Dermatologicals
